Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. 501373-88-2
2. (s)-hydroxy Iloperidone
3. Unii-7sv1zog031
4. 7sv1zog031
5. P-88-8991, (-)-
6. (s)-1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanol
7. Milsaperidone (usan)
8. Milsaperidone [usan]
9. (1s)-1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol
10. Milsaperidone
11. Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-alpha-methyl-, (alphas)-
12. Milsaperidone [inn]
13. Schembl1566323
14. Vhx896
15. Vhx-896
16. Sbkzglwzgzqvha-inizcteosa-n
17. D13099
18. (-)-p-88-8991
19. Q27268802
20. (
21. As)-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-
22. A-methylbenzenemethanol
23. (alphas)-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-alpha-methylbenzenemethanol
24. (s)-1-(4-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)-3-methoxyphenyl)ethan-1-ol
25. (s)-1-[4-{3-[4-(6-fluoro-benzo(d)isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxv-phenyl]-ethanol
26. (s)-1-[4-{3-[4-(6-fluoro-benzo(d)isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenyl]ethanol
| Molecular Weight | 428.5 g/mol |
|---|---|
| Molecular Formula | C24H29FN2O4 |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 68 |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 548 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Milsaperidone, a miscellaneous product targeting 5-HT2A and D2 receptors, shows promise in treating bipolar I disorder.
Lead Product(s): Milsaperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: Bysanti
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milsaperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Vanda Pharma's BYSANTI™ FDA-approved for Bipolar I Disorder and Schizophrenia, a new innovation.
Details : Milsaperidone, a miscellaneous product targeting 5-HT2A and D2 receptors, shows promise in treating bipolar I disorder.
Product Name : Bysanti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 21, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Bysanti (milsaperidone) is a small molecule being investigated for the treatments of acute bipolar I disorder and schizophrenia.
Lead Product(s): Milsaperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: Bysanti
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milsaperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Vanda Submits NDA to FDA for Bysanti for Bipolar I and Schizophrenia
Details : Bysanti (milsaperidone) is a small molecule being investigated for the treatments of acute bipolar I disorder and schizophrenia.
Product Name : Bysanti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Milsaperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Lead Product(s): Milsaperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milsaperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Milsaperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VHX-896 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Milsaperidone,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milsaperidone,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Food Effect Study of VHX-896 in Healthy Volunteers
Details : VHX-896 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VHX-896 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.
Lead Product(s): Milsaperidone,Iloperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milsaperidone,Iloperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Details : VHX-896 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VHX-896 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Milsaperidone,Iloperidone
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milsaperidone,Iloperidone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
Details : VHX-896 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 20, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patents & EXCLUSIVITIES
Patent Expiration Date : 2030-07-24
US Patent Number : 10563259
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4437
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-07-24

Patent Expiration Date : 2030-10-28
US Patent Number : 8999638
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4437
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-10-28

Patent Expiration Date : 2030-12-17
US Patent Number : 9074255
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4436
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-12-17

Patent Expiration Date : 2030-07-24
US Patent Number : 10563259
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4436
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-07-24

Patent Expiration Date : 2030-10-28
US Patent Number : 8999638
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4436
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-10-28

Patent Expiration Date : 2031-02-10
US Patent Number : 9074256
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4436
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-02-10

Patent Expiration Date : 2030-12-17
US Patent Number : 9074255
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4437
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-12-17

Patent Expiration Date : 2028-03-28
US Patent Number : 10570453
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4436
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-03-28

Patent Expiration Date : 2031-01-16
US Patent Number : 9072742
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4437
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-01-16

Patent Expiration Date : 2031-02-10
US Patent Number : 9074256
Drug Substance Claim :
Drug Product Claim :
Application Number : 220358
Patent Use Code : U-4436
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-02-10

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
74
PharmaCompass offers a list of Milsaperidone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Milsaperidone manufacturer or Milsaperidone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Milsaperidone manufacturer or Milsaperidone supplier.
A Milsaperidone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Milsaperidone, including repackagers and relabelers. The FDA regulates Milsaperidone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Milsaperidone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Milsaperidone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Milsaperidone supplier is an individual or a company that provides Milsaperidone active pharmaceutical ingredient (API) or Milsaperidone finished formulations upon request. The Milsaperidone suppliers may include Milsaperidone API manufacturers, exporters, distributors and traders.
click here to find a list of Milsaperidone suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
Milsaperidone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Milsaperidone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Milsaperidone GMP manufacturer or Milsaperidone GMP API supplier for your needs.
A Milsaperidone CoA (Certificate of Analysis) is a formal document that attests to Milsaperidone's compliance with Milsaperidone specifications and serves as a tool for batch-level quality control.
Milsaperidone CoA mostly includes findings from lab analyses of a specific batch. For each Milsaperidone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Milsaperidone may be tested according to a variety of international standards, such as European Pharmacopoeia (Milsaperidone EP), Milsaperidone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Milsaperidone USP).